Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Oct-Dec;8(4):20-7.
doi: 10.14797/mdcj-8-4-20.

Critical limb ischemia: cell and molecular therapies for limb salvage

Mark G Davies  1
Affiliations
Review

Critical limb ischemia: cell and molecular therapies for limb salvage

Mark G Davies. Methodist Debakey Cardiovasc J. 2012 Oct-Dec.

Abstract

There is a growing interest in developing new limb salvage therapies for patients with severe peripheral artery disease who have no alternative to amputation. Cell and gene therapy studies are showing promise in controlling pain and minor ulceration in patients with significant critical limb ischemia. Among cardiovascular cell and molecular therapy programs, The Methodist Hospital is one of the leading centers in both gene and cell therapy for critical limb ischemia. Randomized controlled trials continue to be performed, and these experimental therapies will move from research to pharmacy within the decade. In conjunction with aggressive medical and surgical management, these emergent therapies may help patients with critical limb ischemia avoid a major amputation and are one of the foundations of any advanced limb salvage program.

Keywords: amputation; arteriogenesis; cell therapy; critical limb ischemia; fibroblast growth factor (FGF); gene therapy; hepatocyte growth factor (HGF); limb salvage; molecular therapy; therapeutic angiogenesis; vascular endothelial cell growth factor (VEGF); vasculogenesis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Figure 1
Figure 1
Figure 1
Figure 1
See this image and copyright information in PMC

References

    1. Lawall H, Bramlage P, Amann B. Stem cell and progenitor cell therapy in peripheral artery disease. A critical appraisal. Thromb Haemost. 2010;103:696–709. - PubMed
    1. Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre randomised controlled trial. Lancet. 2005;366:1925–34. - PubMed
    1. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113:e463–654. - PubMed
    1. Risau W. Mechanisms of angiogenesis. Nature. 1997;386(6626):671–4. - PubMed
    1. Hirota K, Semenza GL. Regulation of angiogenesis by hypoxiainducible factor 1. Crit Rev Oncol Hematol. 2006;59:15–26. - PubMed

LinkOut - more resources